Folate hydrolase (prostate-specific antigen) 1 expression in bladder cancer subtypes and associated tumor neovasculature

Modern Pathology

Volumn 24, Issue 11, 2011, Pages 1521-1529

  Samplaski, Mary K ^a   Heston, Warren ^a   Elson, Paul ^a   Magi Galluzzi, Cristina ^a   Hansel, Donna E ^a,b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

adenocarcinoma; bladder; folate hydrolase (prostate specific antigen) 1; PSMA; small cell carcinoma; urothelial carcinoma; vasculature

Indexed keywords

PROSTATE SPECIFIC MEMBRANE ANTIGEN;

ADULT; AGED; ANGIOGENESIS; ARTICLE; BLADDER CANCER; CANCER SURGERY; CANCER SURVIVAL; CYSTECTOMY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SMALL CELL CARCINOMA; SQUAMOUS CELL CARCINOMA; TISSUE MICROARRAY; TRANSITIONAL CELL CARCINOMA; TUMOR VASCULARIZATION;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, SURFACE; CARCINOMA; CARCINOMA, SMALL CELL; CARCINOMA, SQUAMOUS CELL; CHI-SQUARE DISTRIBUTION; DISEASE-FREE SURVIVAL; FEMALE; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PATHOLOGIC; OHIO; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SURVIVAL ANALYSIS; SURVIVAL RATE; TIME FACTORS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 80455174758     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2011.112     Document Type: Article

References (27)

1. American Cancer Society. Bladder Cancer Overview [homepage on the Internet]. American Cancer Society; [updated 1 July 2010; cited 31 August 2010]. Available from: http://www.cancer.org/cancer/bladdercancer/overviewguide/ bladder-cancer-overview-key-statistics.
2. Lane Z, Hansel DE, Epstein JI. Immunohistochemical expression of prostatic antigens in adenocarcinoma and villous adenoma of the urinary bladder. Am J Surg Pathol 2008;32:1322-1326.
3. Israeli RS, Powell CT, Fair WR, et al. Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Cancer Res 1993;53: 227-230. (Pubitemid 23031827)
4. Bostwick DG, Pacelli A, Blute M, et al. Prostate specific membrane antigen expression in prostatic intraepithe-lial neoplasia and adenocarcinoma: a study of 184 cases. Cancer 1998;82:2256-2261. (Pubitemid 28240834)
5. Sweat SD, Pacelli A, Murphy GP, et al. Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology 1998;52:637-640. (Pubitemid 28440171)
6. Kinoshita Y, Kuratsukuri K, Landas S, et al. Expression of prostate-specific membrane antigen in normal and malignant human tissues. World J Surg 2006;30: 628-636.
7. Mhawech-Fauceglia P, Fauceglia P, Zhang S, et al. Prostate-specific membrane antigen (PSMA) protein expression in normal and neoplastic tissues and its sensitivity and specificity in prostate adenocarcinoma: an immunohistochemical study using mutiple tumour tissue microarray technique. Histopathology 2007;50: 472-483. (Pubitemid 46328190)
8. Chang SS, Reuter VE, Heston WD, et al. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res 1999;59:3192-3198. (Pubitemid 29316022)
9. Gala JL, Loric S, Guiot Y, et al. Expression of prostate-specific membrane antigen in transitional cell carcinoma of the bladder: prognostic value? Clin Cancer Res 2000;6:4049-4054.
10. Israeli RS, Powell CT, Corr CT, et al. Expression of the prostate-specific membrane antigen. Cancer Res 1994;54:1807-1811. (Pubitemid 24116191)
11. Chuang AY, DeMarzo AM, Veltri RW, et al. Immuno-histochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma. Am J Surg Pathol 2007;31:1246-1255. (Pubitemid 47207130)
12. Epstein JI. PSA and PAP as immunohistochemical markers in prostate cancer. Urol Clin North Am 1993;20:757-770. (Pubitemid 24141169)
13. Horoszewicz JS, Kawinski E, Murphy GP. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res 1987;7:927-935. (Pubitemid 18036141)
14. Ross JS, Sheehan CE, Fisher HA, et al. Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer. Clin Cancer Res 2003;9:6357-6362. (Pubitemid 38031820)
15. Bander NH, Milowsky MI, Nanus DM, et al. Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol 2005;23:4591-4601. (Pubitemid 46224061)
16. Henry MD, Wen S, Silva MD, et al. A prostate-specific membrane antigen-targeted monoclonal antibody-chemotherapeutic conjugate designed for the treatment of prostate cancer. Cancer Res 2004;64: 7995-8001. (Pubitemid 39446934)
17. Carter RE, Feldman AR, Coyle JT. Prostate-specific membrane antigen is a hydrolase with substrate and pharmacologic characteristics of a neuropeptidase. Proc Natl Acad Sci USA 1996;93:749-753. (Pubitemid 26041162)
18. Haffner MC, Kronberger IE, Ross JS, et al. Prostate-specific membrane antigen expression in the neovas-culature of gastric and colorectal cancers. Hum Pathol 2009;40:1754-1761.
19. Luthi-Carter R, Barczak AK, Speno H, et al. Molecular characterization of human brain N-acetylated alpha-linked acidic dipeptidase (NAALADase). J Pharmacol Exp Ther 1998;286:1020-1025. (Pubitemid 29003499)
20. Mlcochova P, Barinka C, Tykvart J, et al. Prostate-specific membrane antigen and its truncated form PSM'. Prostate 2009;69:471-479.
21. Gordon IO, Tretiakova MS, Noffsinger AE, et al. Prostate-specific membrane antigen expression in regeneration and repair. Mod Pathol 2008;21: 1421-1427.
22. Stroes ES, van Faassen EE, Yo M, et al. Folic acid reverts dysfunction of endothelial nitric oxide synthase. Circ Res 2000;86:1129-1134. (Pubitemid 30396037)
23. Conway RE, Petrovic N, Li Z, et al. Prostate-specific membrane antigen regulates angiogenesis by modulating integrin signal transduction. Mol Cell Biol 2006;26: 5310-5324. (Pubitemid 44036201)
24. Liu H, Moy P, Kim S, et al. Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothe-lium. Cancer Res 1997;57:3629-3634. (Pubitemid 27381196)
25. Chang SS, O'Keefe DS, Bacich DJ, et al. Prostate-specific membrane antigen is produced in tumor-associated neovasculature. Clin Cancer Res 1999;5:2674-2681. (Pubitemid 29493938)
26. Milowsky MI, Nanus DM, Kostakoglu L, et al. Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors. J Clin Oncol 2007;25:540-547. (Pubitemid 350002961)
27. Morris MJ, Pandit-Taskar N, Divgi CR, et al. Phase I evaluation of J591 as a vascular targeting agent in progressive solid tumors. Clin Cancer Res 2007;13: 2707-2713. (Pubitemid 46788039)